MedTest Dx Manufactures the Only FDA Approved Quantitative Test for G6PD, Critical when Considering COVID-19 Treatment with Chloroquine and Hydroxychloroquine ...

Neonatal testing for G6PD deficiency is not yet routine and the American Academy of Pediatrics recommends testing only in jaundiced newborns who are receiving phototherapy whose family history ...

MedTest Dx is manufacturing the only FDA approved quantitative test for G6PD, a critical factor when considering COVID-19 Treatment with chloroquine and hydroxychloroquine.

With G6PD as the first FDA-cleared test on our FINDER platform, we look forward to adding many additional types of tests to the versatile and multifunctional platform." ...

Results of the presently reported screening test were compared with G6PD enzyme levels and glutathione stability tests performed on the same blood samples.

PATH is advancing a portfolio of tests for G6PD deficiency that meet requirements for use in settings where P. vivax malaria is close to elimination. As part of this effort, PATH is working with ...

The World Health Organization (WHO) prequalified the first diagnostic test for glucose-6-phosphate dehydrogenase (G6PD) deficiency which can help to safely deliver WHO-recommended treatments to ...

We conducted a survey of malaria diagnoses and glucose-6-phosphate dehydrogenase (G6PD) testing in remote areas of Cambodia. Blood specimens from 670 people were collected by the finger-prick method.

The World Health Organisation (WHO) has prequalified the first diagnostic test for glucose-6-phosphate dehydrogenase (G6PD) deficiency, a critical tool for safely administering WHO-recommended ...